PubMed for id: 411023

Year	Number of Results
2017	2
2018	1
2019	5
2020	2
2024	0

1

Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.

Bussiere DE, Xie L, Srinivas H, Shu W, Burke A, Be C, Zhao J, Godbole A, King D, Karki RG, Hornak V, Xu F, Cobb J, Carte N, Frank AO, Frommlet A, Graff P, Knapp M, Fazal A, Okram B, Jiang S, Michellys PY, Beckwith R, Voshol H, Wiesmann C, Solomon JM, Paulk J. Bussiere DE, et al. Nat Chem Biol. 2020 Jan;16(1):15-23. doi: 10.1038/s41589-019-0411-6. Epub 2019 Dec 9. Nat Chem Biol. 2020. PMID: 31819272

2

Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.

Du X, Volkov OA, Czerwinski RM, Tan H, Huerta C, Morton ER, Rizzi JP, Wehn PM, Xu R, Nijhawan D, Wallace EM. Du X, et al. Structure. 2019 Nov 5;27(11):1625-1633.e3. doi: 10.1016/j.str.2019.10.005. Structure. 2019. PMID: 31693911 Free article.

3

Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15.

Ting TC, Goralski M, Klein K, Wang B, Kim J, Xie Y, Nijhawan D. Ting TC, et al. Cell Rep. 2019 Nov 5;29(6):1499-1510.e6. doi: 10.1016/j.celrep.2019.09.079. Cell Rep. 2019. PMID: 31693891 Free PMC article.

4

Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.

Faust TB, Yoon H, Nowak RP, Donovan KA, Li Z, Cai Q, Eleuteri NA, Zhang T, Gray NS, Fischer ES. Faust TB, et al. Nat Chem Biol. 2020 Jan;16(1):7-14. doi: 10.1038/s41589-019-0378-3. Epub 2019 Nov 4. Nat Chem Biol. 2020. PMID: 31686031 Free PMC article.

5

A critical evaluation of the approaches to targeted protein degradation for drug discovery.

Chopra R, Sadok A, Collins I. Chopra R, et al. Drug Discov Today Technol. 2019 Apr;31:5-13. doi: 10.1016/j.ddtec.2019.02.002. Epub 2019 Mar 6. Drug Discov Today Technol. 2019. PMID: 31200859 Free PMC article. Review.

6

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Assi R, et al. Cancer. 2018 Jul 1;124(13):2758-2765. doi: 10.1002/cncr.31398. Epub 2018 Apr 16. Cancer. 2018. PMID: 29660836 Free PMC article. Clinical Trial.

7

Selective degradation of splicing factor CAPERα by anticancer sulfonamides.

Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, Kamiyama H, Takahashi K, Kotake Y, Uesugi M, Yokoi A, Inoue A, Yoshida T, Mabuchi M, Tanaka A, Owa T. Uehara T, et al. Nat Chem Biol. 2017 Jun;13(6):675-680. doi: 10.1038/nchembio.2363. Epub 2017 Apr 24. Nat Chem Biol. 2017. PMID: 28437394

8

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.

Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting TC, Xie Y, Williams NS, Nijhawan D. Han T, et al. Science. 2017 Apr 28;356(6336):eaal3755. doi: 10.1126/science.aal3755. Epub 2017 Mar 16. Science. 2017. PMID: 28302793

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year